Related by context. All words. (Click for frequent words.) 79 safety tolerability pharmacokinetics 73 tolerability 72 pharmacokinetics 71 safety tolerability pharmacokinetic 69 pharmacokinetics PK 68 pharmacokinetic profile 67 pharmacodynamics 67 tolerability pharmacokinetics 67 single ascending dose 67 dose escalation trial 66 pharmacodynamic profile 66 pharmacokinetic 66 Phase Ib 66 multiple ascending dose 65 Phase 2a trial 65 dose escalation study 65 pharmacodynamic 65 ascending doses 64 double blind placebo 64 Phase IIa clinical 64 blind placebo controlled 64 tolerated dose MTD 64 pharmacodynamic PD 63 Phase 1b clinical 63 Phase 2a clinical 63 Phase IIa 63 Phase 1b 63 Phase 1a 63 label dose escalation 63 ascending dose 62 placebo controlled 62 immunogenicity 62 Phase Ib clinical 62 blinded randomized placebo controlled 62 pharmacokinetic parameters 62 Phase IIa trial 62 Phase 1b trial 61 blinded placebo controlled 61 pharmacodynamic effects 61 randomized placebo controlled 61 pharmacokinetic profiles 61 Phase 2b study 61 phase Ib 61 safety tolerability pharmacodynamics 60 blind randomized placebo 60 analgesic efficacy 60 randomized double 60 Phase Ia 60 dose cohorts 59 dose escalation Phase 59 phase IIa clinical 59 PXD# 59 pharmacokinetic PK 59 dose escalation clinical 59 masked placebo controlled 59 active comparator 59 pharmacodynamics PD 59 dose limiting toxicities 59 Phase Ib II 59 double blinded placebo 58 dose dose escalation 58 Phase IIb 58 efficacy 58 Phase 2b trial 58 oral prodrug 58 maximally tolerated dose 58 placebo controlled clinical 58 Phase IIb clinical 58 multicenter Phase II 58 PRTX 58 Phase 2a 58 pharmacodynamic properties 58 antiviral activity 58 dosing regimens 58 pharmacokinetics pharmacodynamics 58 phase IIb clinical 58 tolerability profile 57 multicenter randomized double 57 Phase 2b randomized 57 Pharmacokinetics PK 57 phase 2a 57 phase IIa 57 placebo controlled Phase 57 placebo controlled randomized 57 SCH # 57 dose regimens 57 efficacy tolerability 57 davunetide intranasal AL 57 PEG Interferon lambda 57 evaluating tivozanib 57 oral deforolimus 57 dose cohort 57 antitumor activity 57 #mg QD [002] 57 multicenter randomized 57 Phase 2b 57 RSD# oral 57 Phase 2b clinical 57 Phase III clinical 57 Phase 1a clinical 57 PSN# [002] 57 Maximum Tolerated Dose MTD 57 Phase IIb trial 57 achieved statistical significance 57 alvespimycin 56 antiviral efficacy 56 Phase Ib study 56 randomized multicenter 56 galiximab 56 subcutaneous formulation 56 TMC# C# 56 cannabinor 56 Phase IIIb clinical 56 imetelstat 56 investigational protease inhibitor 56 varespladib 56 NGX# 56 Primary endpoints 56 RG# [001] 56 randomized #:# 56 HGS ETR1 56 velafermin 56 novel VDA molecule 56 multicenter randomized placebo controlled 56 riociguat 56 oral rivaroxaban 56 DermaVir Patch 56 LEVADEX 55 MAP# 55 dose escalation 55 multicenter Phase III 55 μg dose 55 randomized controlled 55 CR# vcMMAE 55 nucleotide analog 55 treatment naive genotype 55 randomized clinical 55 Phase Ib clinical trials 55 RDEA# 55 treatment naïve genotype 55 nab paclitaxel 55 JAK inhibitor 55 double blinded randomized 55 phase IIb study 55 tanespimycin 55 fosbretabulin 55 optimal dosing 55 intravesical 55 mg BID 55 dosage regimens 55 randomized Phase III 55 ORMD 55 pharmacokinetic properties 55 confirmatory Phase III 55 forodesine 55 controlled multicenter 55 viral kinetic 55 investigational oral 55 Omacetaxine mepesuccinate 55 plus Copegus R 55 pharmacokinetic studies 55 HCV SPRINT 55 blind randomized 55 blind placebo 55 CIMZIA TM certolizumab pegol 55 dyskinesia PD LID 55 phase IIb 55 Azedra 55 KRN# 55 pivotal Phase 55 pivotal Phase III 55 mg TID 55 preclinical studies 55 viral kinetics 55 desvenlafaxine succinate 55 huN# DM1 55 ongoing Phase 1b 54 pomalidomide 54 virus HCV protease inhibitor 54 PRT# 54 mcg dose 54 INSPIRE Trial Phase III 54 PS# [001] 54 Phase #/#a 54 pharmacodynamic profiles 54 limiting toxicity 54 subcutaneously administered 54 randomized 54 limiting toxicity DLT 54 PPAR gamma agonist 54 dose regimen 54 Secondary endpoints 54 CYT# 54 prospective randomized controlled 54 thorough QT 54 controlled dose escalation 54 trodusquemine 54 multicentre randomized 54 mg dose 54 RG# ITMN 54 adjuvant GIST 54 ZYBRESTAT fosbretabulin 54 Androxal TM 54 GRN#L 54 prospective randomized 54 Traficet EN 54 sorafenib Nexavar ® 54 Initiated Phase 54 randomized Phase 2b 54 subcutaneous SC 54 Phase III randomized 54 teriflunomide 54 Cloretazine R VNP#M 54 teduglutide 54 Phase III placebo controlled 54 administered subcutaneously 54 label multicenter 54 dosing cohort 54 liposomal formulation 54 INCB# [001] 54 investigational compound 54 ritonavir boosted 54 anti leukemic 54 HCV RESPOND 2 54 eculizumab 54 orally bioavailable 54 ACTEMRA TM 54 HGS ETR2 54 telaprevir dosed 54 randomized Phase 54 R#/MEM # 54 8mg/kg 53 posaconazole 53 pharmacokinetic PK profile 53 AKT inhibitor 53 stated Michelle Berrey 53 apremilast 53 celgosivir 53 secondary efficacy endpoints 53 AEGR 53 plasma pharmacokinetics 53 HCD# [002] 53 daunorubicin 53 receptor inhibitor 53 secondary efficacy endpoint 53 omega interferon 53 multicenter 53 selective modulator 53 carboplatin 53 GAMMAGARD 53 diabetic neuropathic pain 53 nitazoxanide 53 thymalfasin 53 MEND CABG 53 randomized controlled Phase 53 phase Ib clinical 53 IMGN# 53 orally administered 53 prucalopride 53 BRIM2 53 Panzem R NCD 53 dosed orally 53 vidofludimus 53 bicifadine 53 iobenguane 53 recurrent malignant glioma 53 pharmacokinetic pharmacodynamic 53 placebo controlled dose escalation 53 Forodesine HCl 53 ascending dose study 53 MGd 53 dosing cohorts 53 GLYX 53 primary endpoint 53 II Clinical Trial 53 CIMZIA ™ 53 Phase 1b clinical trials 53 randomized controlled clinical 53 neratinib 53 preclinical efficacy 53 Phase IIb trials 53 erlotinib Tarceva ® 53 hypoxia activated prodrug 53 fluticasone furoate 53 docetaxel Taxotere R 53 ganetespib 53 maximal tolerated 53 unique alkylating agent 53 oral bioavailability 53 CIMZIA TM 53 randomized blinded 53 alfa 2a 53 heavily pretreated 53 placebo controlled Phase III 53 Empatic 53 tolerability profiles 53 bendamustine 53 pegylated interferon alfa 2a 53 intravenous dosing 53 NP2 Enkephalin 53 relapsed MM 53 Azixa 53 Exelixis compounds 53 Multimeric 53 Initiate Phase 53 polymerase inhibitor 53 reactogenicity 53 ELACYT 53 mertansine 53 demonstrated antitumor activity 53 visilizumab 53 clinical trial 53 bevirimat Study 52 evaluable patients 52 CEQ# 52 tasimelteon 52 mapatumumab 52 PEG PAL 52 prospectively defined 52 bosentan 52 Phase 1b dose escalation 52 IIa trial 52 AAG geldanamycin analog 52 recurrent glioblastoma multiforme 52 Sym# 52 weekly subcutaneous injections 52 Sapacitabine 52 systemically administered 52 Blinatumomab 52 mg QD 52 CLORETAZINE TM VNP#M 52 beclomethasone dipropionate 52 protease inhibitor PI 52 lisdexamfetamine dimesylate 52 elotuzumab 52 eltrombopag 52 PRX # 52 CTA# Injection 52 plus prednisone 52 CG# [003] 52 IIa clinical 52 melphalan prednisone 52 MAGE A3 ASCI 52 CRESTOR #mg 52 refractory CLL 52 biodistribution 52 coadministration 52 radiation dosimetry 52 eniluracil 52 Phase #b/#a trial 52 dexamethasone Decadron 52 avosentan 52 prospective observational 52 antitumor effect 52 initiate Phase 1b 52 intermittent dosing 52 COU AA 52 solithromycin 52 BAY #-# 52 plus ribavirin 52 sunitinib malate 52 investigational drug 52 Posiphen 52 mGluR5 NAM 52 MEND CABG II 52 prospective multicenter randomized 52 monotherapy 52 interferon gamma 1b 52 multicenter multinational 52 bioavailability 52 Interferon alpha 52 pharmacokinetic equivalence 52 dose escalation phase 52 relapsed refractory multiple myeloma 52 receiving INTRON 52 Secondary endpoints include 52 urate lowering 52 plus prednisone prednisolone 52 JVRS 52 nucleoside analog 52 lead Aganocide compound 52 rNAPc2 52 CK # 52 preclinically 52 PF # [001] 52 LUX Lung 52 mcg kg 52 multicenter Phase 52 Pegasys ® 52 venlafaxine XR 52 Triolex 52 pharmacodynamic markers 52 PKC# 52 DLTs 52 pertuzumab 52 placebo controlled clinical trials 52 refractory NSCLC 52 sunitinib Sutent ® 52 cilengitide 52 ENVISION 52 albinterferon alfa 2b 52 CCR5 mAb 52 administered orally 52 oral ridaforolimus 52 Enzastaurin 52 Darusentan 52 humanized anti 52 trial evaluating PRX# 52 IIIa inhibitor 52 PEGylated interferon beta 1a 52 Apoptone 52 INCB# [002] 52 #mg/m# [002] 52 oral formulation 52 Pralatrexate 52 HCV NS5B polymerase 52 ANA# 52 plus dexamethasone 52 TOLAMBA 52 Immunogenicity 52 prospective multicenter 52 AZILECT R 52 Ophena TM 52 erythropoietic 52 nonrandomized 52 Phase 2b clinical trials 52 hyperphenylalaninemia HPA due 52 intravesical instillation 52 FOLFOX6 chemotherapy regimen 52 novel histone deacetylase 52 LEP ETU 52 relapsed refractory 51 metastatic HRPC 51 Bezielle 51 NEUGENE antisense 51 dose pharmacokinetic 51 daily subcutaneous injections 51 romidepsin 51 Phase #/#a clinical 51 ALN TTR# 51 PDE4 inhibitor 51 Phase IIIb 51 #mg/m# [001] 51 rALLy clinical trial 51 randomized discontinuation trial 51 sorafenib Nexavar 51 APTIVUS r 51 Fx #A 51 fallopian tube cancers 51 Omacetaxine 51 metastatic hormone refractory 51 CB2 selective receptor agonist 51 recurrent genital herpes 51 Phase III confirmatory 51 CTCE 51 crizotinib PF # 51 Phase IIB 51 ofatumumab 51 pharmacokinetic characteristics 51 MEK inhibitor RDEA# 51 label multicenter Phase 51 #mg BID [003] 51 ADVANCE PD 51 lexidronam injection 51 chlorambucil 51 noninferiority 51 peripherally acting 51 TPI ASM8 51 registrational 51 ara C 51 telaprevir dosing 51 aflibercept VEGF Trap 51 Ceplene/IL-2 51 IAP inhibitor 51 multicenter randomized Phase 51 TG# [001] 51 metaglidasen 51 CTAP# Capsules 51 prokinetic agent 51 lomitapide 51 Pharmacokinetic 51 brivaracetam 51 non inferiority 51 primary hypercholesterolemia 51 Multiple Ascending Dose 51 Oral Fingolimod 51 NO# [002] 51 ARRY 51 MGCD# [002] 51 Phase IIa trials 51 randomized multicenter trial 51 Phase Ib IIa 51 INCB# [003] 51 torezolid phosphate 51 ZD# [001] 51 dasatinib Sprycel ® 51 mcg BID 51 favorable pharmacokinetic profile 51 CANCIDAS 51 Engerix B 51 SILENOR TM 51 HGS# 51 inhibitor RG# 51 multicenter randomized controlled 51 CorVue ™ 51 null responder HCV 51 REOLYSIN ® 51 zonisamide SR 51 dosing schedules 51 docetaxel chemotherapy 51 intravenously administered 51 RE SURGE 51 lintuzumab 51 Laquinimod 51 CDK inhibitor 51 EZN 51 cell lymphoma CTCL 51 multicentre randomized double 51 receptor tyrosine kinase inhibitor 51 AQ4N 51 low dose dexamethasone 51 axitinib 51 EXPLORE Xa 51 mg RDEA# 51 Aplidin R 51 highly selective inhibitor 51 abacavir lamivudine 51 6R BH4 51 prospective randomized multicenter 51 intranasal formulation 51 Dapagliflozin 51 velafermin belinostat 51 IMC A# 51 #mg/day [001] 51 docetaxel 51 AEG# 51 TMC# [002] 51 efficacy endpoints 51 pharmacokinetic PK study 51 huC# DM4 51 efficacy endpoint 51 Prodarsan ® 51 Randomized Phase 51 PDX pralatrexate 51 AIR CF1 51 incyclinide 51 cutaneous T cell 51 TASKi2 51 STEALTH C 51 TO AVOID PREGNANCY WHILE 51 Amrubicin 51 #mg dose [001] 51 Valortim 51 PREZISTA r 51 FOLOTYN ® 51 ritonavir boosted atazanavir 51 Phase IIb III 51 blinded randomized 51 beta2 agonist 51 blind multicenter 51 PEG IFN 51 evaluating REVLIMID 51 OMNARIS HFA 51 Secondary efficacy endpoints 51 oral sapacitabine 51 AIR CF2 51 subcutaneous doses 51 rhIGF-I/rhIGFBP-3 51 prasterone 51 Mg Uk 51 CK # administered 51 investigational monoclonal antibody 51 Imprime PGG 51 Linaclotide 51 dirucotide MBP# 51 PEGPH# 51 Parkinson disease levodopa induced 51 NOX E# 51 CRp 51 paclitaxel poliglumex 51 tezampanel 51 secondary endpoints 51 systemic RNAi therapeutic 51 OncoVEX GM CSF 51 Chemophase 51 APOPTONE 51 APTIVUS 51 PEG SN# 51 ZYBRESTAT 51 randomized crossover 51 CaPre TM 51 adecatumumab MT# 51 statistically significant superiority 51 PSMA ADC 51 HER2 positive metastatic breast 51 BMS# 51 mg qd 51 composite endpoint 51 painful diabetic neuropathy 51 Phase IIb randomized 51 Kinoid 51 pharmacodynamic endpoints 51 GW# [003] 51 leukemia AML 51 Pharmacokinetic parameters 50 dose interleukin 50 efavirenz EFV 50 TBC# 50 ruxolitinib 50 label multicenter randomized 50 relapsing multiple sclerosis 50 ENMD # 50 RoACTEMRA 50 histamine dihydrochloride 50 MORAb 50 anti amnesic 50 TAXUS VI 50 endothelin antagonists 50 Dual Opioid 50 confirmatory clinical 50 Alzhemed TM 50 gemcitabine Gemzar ® 50 liposomal doxorubicin 50 preclinical 50 Oral NKTR 50 glatiramer acetate 50 BRIM3 50 evaluable 50 Zenvia ™ 50 Phase #b/#a 50 Tarvacin TM 50 sorafenib tablets 50 reslizumab 50 primary efficacy endpoint 50 bavituximab 50 preclinical models 50 initiate Phase IIa 50 GLPG# 50 Phase IIIb study 50 vandetanib 50 XP# Transported Prodrug 50 oral methylnaltrexone 50 Sanofi Pasteur Fluzone 50 PNP inhibitor 50 comparator arm 50 PRECiSE 50 serotonin norepinephrine reuptake inhibitor 50 mcg albinterferon alfa 2b 50 estramustine 50 CRLX# 50 enzastaurin 50 mg kg BID 50 VELCADE melphalan 50 tgAAC# 50 Pharmacokinetic studies 50 registrational Phase 50 adecatumumab 50 lorvotuzumab mertansine 50 multicenter placebo controlled 50 hemagglutination inhibition HAI 50 immunomodulator 50 LEXIVA r 50 blind randomized controlled 50 mg kg dose 50 bazedoxifene conjugated estrogens 50 Phase #b/#a clinical 50 peripheral blood mononuclear 50 Cloretazine 50 cariprazine 50 albiglutide 50 REMINYL ® 50 Solid Tumors 50 USL# 50 naïve HCV 50 azacitidine 50 ganaxolone 50 Kahalalide F 50 ANCHOR trial 50 Tarceva TM 50 Archexin 50 next generation URAT1 50 investigational humanized monoclonal antibody 50 R# #mg BID 50 REVIVE Diabetes 50 salmeterol fluticasone 50 REG2 50 AP# [003] 50 antiviral potency 50 refractory chronic lymphocytic 50 Phase III 50 selective agonist 50 First Patient Dosed 50 Phase III randomized controlled 50 ONTARGET 50 depsipeptide 50 GATTEX ™ 50 Liposomal 50 systemic immunosuppressive drugs 50 PRE SURGE 50 initiate Phase 50 carboplatin paclitaxel 50 LAB CGRP 50 Phase III clinical trials 50 placebo controlled multicenter 50 RGB # 50 APPRAISE 50 VNP#M 50 5 HT2C receptor 50 Navelbine 50 Teriflunomide 50 subcutaneous dose 50 multicenter clinical 50 ATACAND 50 tirofiban 50 MYCAMINE 50 antidepressant efficacy 50 Preclinical studies suggest 50 bevirimat 50 bupropion SR 50 multicentre 50 multinational multicenter randomized 50 NPH insulin 50 By JENNIFER LEARN 50 2 methoxyestradiol 50 partial agonist 50 doxorubicin cyclophosphamide 50 ocular formulation 50 Phase II 50 randomized controlled multicenter 50 lymphoma CTCL 50 MIRCERA 50 peginterferon alfa 2a 50 nucleoside reverse transcriptase inhibitor 50 pramlintide 50 REVLIMID lenalidomide 50 PI3K/Akt pathway inhibitor 50 SAR# [004] 50 neuroprotective effects 50 EVIZON 50 MEK inhibitor 50 GSK# [001] 50 pramlintide metreleptin combination 50 neurogenic orthostatic hypotension 50 Antiviral Activity 50 mg/m2/day 50 Alocrest 50 plasma concentrations 50 vapreotide acetate 50 Interferon beta 1a 50 Tolerability 50 HIV HCV coinfected 50 eosinophilic asthma 50 prospective cohort 50 TG# [003] 50 remission CR 50 mixed hyperlipidemia 50 non splenectomized 50 mg BID dose 50 Peginterferon 50 metreleptin 50 q8h 50 dacetuzumab 50 pregabalin Lyrica 50 events AEs 50 TH# [003] 50 sulodexide 50 antibody MAb 50 NSABP B 50 pegylated interferon alfa 2b 50 Debio 50 Denufosol 50 orally inhaled migraine 50 morphometric vertebral fractures 50 ChronVac C R 50 olmesartan 50 multicenter phase 50 selective androgen receptor modulator 50 Clinical Antipsychotic Trials 50 nonclinical studies 50 castrate resistant prostate cancer 50 Hsp# Inhibitor 50 EFAPROXYN 50 virological response 50 CRx 50 topical formulation 50 generation purine nucleoside 50 plus COPEGUS 50 highly immunogenic 50 NOXAFIL Oral Suspension 50 mRCC 50 orally dosed 50 phase IIb trial 50 Solid Tumors criteria 50 peginterferon alfa 2b 50 Phase 2b Trial 50 Microplasmin 50 Tolvaptan 50 vivo efficacy 50 urocortin 2 50 atazanavir ritonavir 50 Vaxfectin TM adjuvant 50 Anturol TM 50 gemcitabine 50 ribavirin RBV 50 Darinaparsin 50 Intervention Effectiveness 50 randomized multicenter Phase III 50 resolvin 50 Protease Inhibitor 50 placebo controlled studies 50 virus HCV infection 49 Doxil ® 49 sodium glucose cotransporter 49 peginterferon alfa 2a #KD 49 MoxDuo TM IR 49 Solid Tumours 49 QLT# 49 FOLFOX6 49 candesartan cilexetil 49 vicriviroc 49 Carfilzomib 49 xenograft models 49 omecamtiv mecarbil 49 pegylated interferon alpha 49 Val HeFT 49 ABSORB clinical 49 Cannabinor 49 baminercept 49 budesonide foam 49 ILLUMINATE 49 ExTRACT TIMI 49 docetaxel Taxotere ® 49 unresectable HCC 49 glucose lowering 49 interferon alfa 2b 49 secondary endpoint 49 oral dosing 49 dosing regimen 49 nucleoside naive 49 Golimumab 49 symptomatic BPH 49 investigational hepatitis C 49 hour bronchodilation 49 GRNVAC1 49 TACI Ig 49 EGFR HER2 49 urinary N telopeptide 49 CR CRu 49 voreloxin 49 Curaxin CBLC# 49 hematologic malignancies 49 ALB # 49 Pegasys plus Copegus 49 DEB# 49 μg kg 49 Virulizin ® 49 administered intranasally 49 virologic 49 Phase IIb clinical trials 49 ASH Abstract # 49 randomized Phase IIb 49 ataluren 49 adipiplon 49 Initiates Phase II 49 Tasimelteon 49 AERAS-#/Crucell Ad# 49 designated HVTN 49 imatinib resistant 49 oxycodone CR 49 potent antiviral 49 AZX# 49 Cloretazine ® 49 GOUT 49 deforolimus 49 Copegus ® ribavirin 49 low dose cytarabine 49 post herpetic neuralgia PHN 49 Hsp# inhibitor 49 lintuzumab SGN 49 SinuNase TM 49 metastatic renal cell carcinoma 49 Phase IIA 49 radezolid 49 HMG CoA reductase inhibitor 49 MyVax R 49 CBLC# 49 Randomized Double blind 49 PROCHYMAL 49 ALISTA 49 alagebrium 49 flibanserin #mg 49 TELINTRA 49 vivo toxicology 49 mg/m2 cohort 49 TAXUS ATLAS 49 IFN α 49 synthetic retinoid 49 VIRAMUNE XR 49 demonstrated clinically meaningful 49 saline placebo 49 relapsed MCL 49 APEX PD 49 OMP #M# 49 Telintra 49 Natalizumab 49 Triapine R 49 HCV genotype 1 49 certolizumab 49 tolterodine ER 49 DAVANAT 49 dose cytarabine 49 lamivudine zidovudine 49 Preclinical studies 49 boosted protease inhibitor 49 subanalysis 49 mg doses 49 CoFactor 49 Xanafide 49 vorinostat 49 dyslipidaemia 49 antiangiogenic activity 49 Secondary endpoints included 49 GATTEX ® 49 trastuzumab Herceptin R 49 HZT 49 COMFORT II 49 GFT# 49 AeroLEF TM 49 RH1 49 daily Infergen 49 vivo preclinical 49 HDAC inhibitor 49 Acute Ischemic Stroke 49 Staccato prochlorperazine 49 severe oral mucositis 49 edoxaban 49 trastuzumab emtansine T DM1 49 TASKi3 49 ARIKACE 49 immunomodulatory effects 49 Diamyd ® 49 dextromethorphan quinidine 49 TLK# 49 plus gemcitabine 49 peginterferon alpha 2a 49 pegylated interferon peg IFN 49 Phase Ib Clinical Trial 49 bortezomib Velcade R 49 TMC# r 49 XL# [003] 49 ostarine 49 Phase 2a Clinical Trial 49 Sorafenib HCC Assessment 49 randomized controlled trial 49 humanized interleukin 6 49 CYT# QbG# 49 label dose titration 49 generation PNP inhibitor 49 mg/m2 49 LT NS# 49 ROZEREM TM 49 oral Janus kinase 49 afatinib 49 peg IFN 49 EDEMA3 trial 49 AzaSite Plus 49 dabigatran etexilate 49 parathyroid hormone PTH 49 trials RCTs 49 diabetic gastroparesis 49 S/GSK# 49 Panzem R 49 MVA MUC1 IL2 49 quadrivalent HPV vaccine 49 immunotherapeutic agent 49 RE LY ® 49 Annamycin 49 Prodarsan 49 angiotensin receptor blocker ARB 49 PEG INTRON R 49 perifosine KRX 49 Methylnaltrexone 49 PET FROM 49 antiretroviral naïve 49 randomized multicentre 49 oral renin inhibitor 49 PRIMO CABG2 49 High Dose quadruples 49 metastatic RCC 49 HspE7 49 bepotastine besilate nasal spray 49 Valortim ® 49 imetelstat GRN#L 49 mycophenolate mofetil 49 pharmacokinetic interactions 49 #mg/day [002] 49 REYATAZ r 49 Atiprimod 49 retapamulin